These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22952345)

  • 1. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
    Brown JE; Cook RJ; Lipton A; Coleman RE
    Clin Cancer Res; 2012 Nov; 18(22):6348-55. PubMed ID: 22952345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
    Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
    Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.
    Brown JE; Cook RJ; Lipton A; Costa L; Coleman RE
    Breast Cancer Res Treat; 2010 Oct; 123(3):767-79. PubMed ID: 20574672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
    Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
    Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
    J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and prognostic factors in patients with bone metastases from non-small cell lung cancer.
    Wu XT; Zhou JW; Pan LC; Ge T
    J Int Med Res; 2020 May; 48(5):300060520925644. PubMed ID: 32425092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
    Zhao X; Xu X; Zhang Q; Jia Z; Sun S; Zhang J; Wang B; Wang Z; Hu X
    BMC Cancer; 2011 Sep; 11():403. PubMed ID: 21936956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association between Fever and Prognosis in Lung Cancer Patients with Bone Metastases Receiving Zoledronic Acid.
    Sunaga T; Shimamoto K; Nakamura S; Takahashi N; Higashino M; Hozumi T; Matsui M; Nagatani A; Kokubu F; Kogo M; Sasaki T
    Chemotherapy; 2017; 62(6):327-333. PubMed ID: 28605733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
    Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
    Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
    Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.
    Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F; Smith MR
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3361-7. PubMed ID: 16740758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
    Coleman RE
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
    Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.